State-of-the-Art 2019 on Gene Therapy for Phenylketonuria

Hiu Man Grisch-Chan, Gerald Schwank, Cary O. Harding, Beat Thöny

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Phenylketonuria (PKU) is considered to be a paradigm for a monogenic metabolic disorder but was never thought to be a primary application for human gene therapy due to established alternative treatment. However, somewhat unanticipated improvement in neuropsychiatric outcome upon long-term treatment of adults with PKU with enzyme substitution therapy might slowly change this assumption. In parallel, PKU was for a long time considered to be an excellent test system for experimental gene therapy of a Mendelian autosomal recessive defect of the liver due to an outstanding mouse model and the easy to analyze and well-defined therapeutic end point, that is, blood l-phenylalanine concentration. Lifelong treatment by targeting the mouse liver (or skeletal muscle) was achieved using different approaches, including (1) recombinant adeno-associated viral (rAAV) or nonviral naked DNA vector-based gene addition, (2) genome editing using base editors delivered by rAAV vectors, and (3) by delivering rAAVs for promoter-less insertion of the PAH-cDNA into the Pah locus. In this article we summarize the gene therapeutic attempts of correcting a mouse model for PKU and discuss the future implications for human gene therapy.

Original languageEnglish (US)
Pages (from-to)1274-1283
Number of pages10
JournalHuman Gene Therapy
Volume30
Issue number10
DOIs
StatePublished - Oct 2019

Fingerprint

Phenylketonurias
Genetic Therapy
Enzyme Therapy
Therapeutics
Investigational Therapies
Liver
Phenylalanine
Genes
Skeletal Muscle
Complementary DNA
DNA

Keywords

  • base editing
  • gene delivery
  • liver gene therapy
  • nonviral minicircle vector
  • rAAV

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

State-of-the-Art 2019 on Gene Therapy for Phenylketonuria. / Grisch-Chan, Hiu Man; Schwank, Gerald; Harding, Cary O.; Thöny, Beat.

In: Human Gene Therapy, Vol. 30, No. 10, 10.2019, p. 1274-1283.

Research output: Contribution to journalReview article

Grisch-Chan, HM, Schwank, G, Harding, CO & Thöny, B 2019, 'State-of-the-Art 2019 on Gene Therapy for Phenylketonuria', Human Gene Therapy, vol. 30, no. 10, pp. 1274-1283. https://doi.org/10.1089/hum.2019.111
Grisch-Chan, Hiu Man ; Schwank, Gerald ; Harding, Cary O. ; Thöny, Beat. / State-of-the-Art 2019 on Gene Therapy for Phenylketonuria. In: Human Gene Therapy. 2019 ; Vol. 30, No. 10. pp. 1274-1283.
@article{9a58cb9891f64b7e96267710e281568f,
title = "State-of-the-Art 2019 on Gene Therapy for Phenylketonuria",
abstract = "Phenylketonuria (PKU) is considered to be a paradigm for a monogenic metabolic disorder but was never thought to be a primary application for human gene therapy due to established alternative treatment. However, somewhat unanticipated improvement in neuropsychiatric outcome upon long-term treatment of adults with PKU with enzyme substitution therapy might slowly change this assumption. In parallel, PKU was for a long time considered to be an excellent test system for experimental gene therapy of a Mendelian autosomal recessive defect of the liver due to an outstanding mouse model and the easy to analyze and well-defined therapeutic end point, that is, blood l-phenylalanine concentration. Lifelong treatment by targeting the mouse liver (or skeletal muscle) was achieved using different approaches, including (1) recombinant adeno-associated viral (rAAV) or nonviral naked DNA vector-based gene addition, (2) genome editing using base editors delivered by rAAV vectors, and (3) by delivering rAAVs for promoter-less insertion of the PAH-cDNA into the Pah locus. In this article we summarize the gene therapeutic attempts of correcting a mouse model for PKU and discuss the future implications for human gene therapy.",
keywords = "base editing, gene delivery, liver gene therapy, nonviral minicircle vector, rAAV",
author = "Grisch-Chan, {Hiu Man} and Gerald Schwank and Harding, {Cary O.} and Beat Th{\"o}ny",
year = "2019",
month = "10",
doi = "10.1089/hum.2019.111",
language = "English (US)",
volume = "30",
pages = "1274--1283",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "10",

}

TY - JOUR

T1 - State-of-the-Art 2019 on Gene Therapy for Phenylketonuria

AU - Grisch-Chan, Hiu Man

AU - Schwank, Gerald

AU - Harding, Cary O.

AU - Thöny, Beat

PY - 2019/10

Y1 - 2019/10

N2 - Phenylketonuria (PKU) is considered to be a paradigm for a monogenic metabolic disorder but was never thought to be a primary application for human gene therapy due to established alternative treatment. However, somewhat unanticipated improvement in neuropsychiatric outcome upon long-term treatment of adults with PKU with enzyme substitution therapy might slowly change this assumption. In parallel, PKU was for a long time considered to be an excellent test system for experimental gene therapy of a Mendelian autosomal recessive defect of the liver due to an outstanding mouse model and the easy to analyze and well-defined therapeutic end point, that is, blood l-phenylalanine concentration. Lifelong treatment by targeting the mouse liver (or skeletal muscle) was achieved using different approaches, including (1) recombinant adeno-associated viral (rAAV) or nonviral naked DNA vector-based gene addition, (2) genome editing using base editors delivered by rAAV vectors, and (3) by delivering rAAVs for promoter-less insertion of the PAH-cDNA into the Pah locus. In this article we summarize the gene therapeutic attempts of correcting a mouse model for PKU and discuss the future implications for human gene therapy.

AB - Phenylketonuria (PKU) is considered to be a paradigm for a monogenic metabolic disorder but was never thought to be a primary application for human gene therapy due to established alternative treatment. However, somewhat unanticipated improvement in neuropsychiatric outcome upon long-term treatment of adults with PKU with enzyme substitution therapy might slowly change this assumption. In parallel, PKU was for a long time considered to be an excellent test system for experimental gene therapy of a Mendelian autosomal recessive defect of the liver due to an outstanding mouse model and the easy to analyze and well-defined therapeutic end point, that is, blood l-phenylalanine concentration. Lifelong treatment by targeting the mouse liver (or skeletal muscle) was achieved using different approaches, including (1) recombinant adeno-associated viral (rAAV) or nonviral naked DNA vector-based gene addition, (2) genome editing using base editors delivered by rAAV vectors, and (3) by delivering rAAVs for promoter-less insertion of the PAH-cDNA into the Pah locus. In this article we summarize the gene therapeutic attempts of correcting a mouse model for PKU and discuss the future implications for human gene therapy.

KW - base editing

KW - gene delivery

KW - liver gene therapy

KW - nonviral minicircle vector

KW - rAAV

UR - http://www.scopus.com/inward/record.url?scp=85072849420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072849420&partnerID=8YFLogxK

U2 - 10.1089/hum.2019.111

DO - 10.1089/hum.2019.111

M3 - Review article

C2 - 31364419

AN - SCOPUS:85072849420

VL - 30

SP - 1274

EP - 1283

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 10

ER -